Marcolin Reports Growth, Stable Revenues in 2024

Published on May 9, 2025
LONGARONE and MILAN, Italy—On March 26, 2025, the board of directors of Marcolin presented the draft of the Group’s separate and consolidated financial statements for the year ended December 31, 2024, which will be approved by the Shareholders’ Meeting on April 7, 2025, the Group said. In 2024, Marcolin said it successfully strengthened its performance, continuing the growth path of recent years with improvements in profitability. For 2024, Marcolin’s adjusted EBITDA reached €85.0 million (+10.2 percent year over year), with a margin on net sales of 15.6 percent, up from 13.8 percent in 2023.
Continue reading on website
Other news

CIME 2025: Luke Lindsell, OD, MD, on bridging innovation and practical care in retinal disease

May 8, 2025
Lindsell discusses promising retinal therapeutics, such as at-home therapies, gene therapy, and devices like the Valeda light delivery system (LumiThera), which uses photobiomodulation and shows early promise in preventing geographic atrophy altogether.

Prevent Blindness voices support for reintroduction of EDVI Act

May 9, 2025
The Early Detection of Vision Impairments for Children Act (EDVI), or HR 2527, would allow the federal government to award grants and cooperative agreements to eligible states and communities for children's vision care initiatives.